7th Oct 2021 20:32
Renalytix PLC - Cardiff, Wales-based clinical diagnostics for kidney disease - Announces expansion of its commercial strategy to address early-stage kidney disease in Veterans Health Administration patients with the appointment of Jed Fulk as its new vice president of sales, government accounts. The move is intended to help to support the rollout of KidneyIntelX to the veterans health system. KidneyIntelX will be deployed to help veterans health physicians to identify diabetic kidney disease patients at high and low risk for rapid progression and kidney failure, it adds.
Current stock price: 780.00 pence
Year-to-date change: up 42%
By Arvind Bhunjun; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc